Physician profile
David Mostafavi
NPI 1144453671
$3,551.56
in general payments reported to CMS, 2019-2025
24 companies · $577 in 2025
The $577 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $185 · 2021: $109 · 2022: $397 · 2023: $961 · 2024: $800 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.80 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $457.89 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $449.16 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $392.28 | 2019-2025 | Eysuvis, Hydrus Microstent, Tryptyr |
| Bausch & Lomb Americas INC. | $306.91 | 2023-2025 | Envista Mx60 Iol, Envista Aspire Toric Iol, Miebo |
| Dompe US, INC. | $299.40 | 2022-2024 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $244.94 | 2022-2023 | Eylea |
| Kala Pharmaceuticals, INC. | $184.86 | 2019-2021 | |
| Abbvie INC. | $152.78 | 2022-2025 | |
| Alimera Sciences, INC. | $143.02 | 2024 | Iluvien, Yutiq |
| Harrow Eye, LLC | $141.08 | 2025 | Vevye |
| Astellas Pharma US INC | $124.87 | 2024 | Izervay |
| Aerie Pharmaceuticals, INC. | $123.12 | 2019 | |
| Allergan, INC. | $111.39 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $70.75 | 2019-2024 | Tecnis Iol |
| Ani Pharmaceuticals, INC. | $68.86 | 2024-2025 | Purified Cortrophin Gel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $57.35 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $52.68 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $33.02 | 2023-2025 | Dextenza |
| Rxsight INC | $31.47 | 2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.25 | 2020-2021 | |
| Shire North American Group INC | $25.67 | 2019 | |
| New World Medical,INC. | $23.78 | 2023 | |
| Eyevance Pharmaceuticals LLC | $17.79 | 2019 | |
| Beaver-Visitec International, INC. | $9.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mostafavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.